What is the history of Fabry disease?

Fabry disease was independently discovered in 1898 by dermatologists Johannes Fabry and William Anderson, who initially identified it through its characteristic skin manifestations. Since that time, our understanding has shifted from viewing Fabry disease solely as a dermatological issue to recognizing it as a systemic, life-threatening lysosomal storage disorder caused by a deficiency of the enzyme alpha-galactosidase A.

How was Fabry disease first discovered?

In 1898, the condition was described independently by Dr. Johannes Fabry in Germany and Dr. William Anderson in England. Both physicians observed patients with a distinct, widespread reddish-purple skin rash, which we now know as angiokeratomas. At the time, they named the condition "angiokeratoma corporis diffusum." For decades, the medical community viewed this primarily as a skin disease, unaware of the underlying metabolic dysfunction occurring within the vital organs. It was not until the mid-20th century that researchers began to understand that these skin lesions were merely a external marker for a much broader, systemic pathology affecting the heart, kidneys, and nervous system.

How has our understanding of Fabry disease evolved?

The true breakthrough occurred in the 1960s when researchers identified that Fabry disease is a lysosomal storage disorder. Specifically, scientists discovered that patients lack the functional enzyme alpha-galactosidase A, leading to the toxic accumulation of a fatty substance called globotriaosylceramide (GL-3 or Gb3) in cells throughout the body. This scientific pivot transformed Fabry disease from a dermatological curiosity into a complex metabolic condition. With the advent of molecular genetics in the 1980s and 1990s, the gene responsible for the condition—the GLA gene located on the X chromosome—was mapped, allowing for accurate genetic testing and carrier detection.

What are the major milestones in treatment development?

The history of treatment for Fabry disease represents a remarkable journey of medical innovation:

• 1970s: Initial attempts at enzyme replacement were explored but were limited by technology.


• 2001: The first Enzyme Replacement Therapy (ERT) was approved, providing patients with a synthetic version of the missing alpha-galactosidase A enzyme.


• 2016: Oral chaperone therapy was introduced for patients with specific "amenable" mutations, offering a different mechanism to stabilize the body's own existing enzyme.


• Ongoing: Current research is aggressively pursuing gene therapy and substrate reduction therapy to improve long-term outcomes for those living with Fabry disease.

How has patient advocacy changed the landscape?

Historically, patients with Fabry disease often faced years of diagnostic delays due to the rarity and multisystem nature of the condition. The rise of patient advocacy groups has been vital in correcting misconceptions, such as the outdated belief that only males were severely affected. We now know that females, due to X-inactivation patterns, can also experience severe, life-limiting symptoms. Today, platforms like DiseaseMaps.org, which supports 174 members currently living with Fabry disease, foster global connections that help bridge the gap between clinical research and the lived patient experience.

Next steps

• Consult with a metabolic geneticist or a cardiologist specializing in lysosomal storage disorders to discuss the latest management protocols.


• Join the Fabry disease community on DiseaseMaps.org to connect with others who share your lived experience.


• Speak with your medical team about whether you qualify for clinical trials exploring new gene-editing or chaperone therapies.

Medical disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases (GARD) Information Center: Fabry Disease Overview.


• Orphanet: Fabry Disease (ORPHA324).


• Online Mendelian Inheritance in Man (OMIM): Alpha-galactosidase A deficiency (#301500).


• National Fabry Disease Foundation (NFDF): Historical Perspective and Patient Resources.